GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of how much of what we believe about endpoint actually comes from FLOW threads — 31 comments in the full submission. View in context.
479
c/trialwatch·submitted 2 months ago by u/nhs_waitlist_n

how much of what we believe about endpoint actually comes from FLOW threads

Statsbranch of 9 comments

Question in the title, detail here: how much of what we believe about endpoint actually comes from FLOW threads. Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking. How to read one of these papers in fifteen minutes, in the order that…

Read the full submission and all 31 comments →

This branch

9 comments, started 2 months ago
u/forest_plot_fionaMOD87 points·2 months ago

Retitled: the original quoted a diabetes endpoint as an obesity result.

replysharereportpermalink
u/renal_outcomes_rnephro-curious108 points·2 months ago

read the endpoint before you read the headline

replysharereportpermalink
u/draw_up_dizzy34 points·2 months ago

intention to treat versus completers changes the number substantially

replysharereportpermalink
u/yannick_salinas26 points·2 months ago

SURPASS is the diabetes programme and reports glycaemic endpoints

replysharereportpermalink
u/nhs_waitlist_nOPUK14 points·2 months ago

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/slow_logbook_notes3030 points·2 months ago

What was the comparator?

replysharereportpermalink
u/week_four_wall30 points·2 months ago

Cosigning on discontinuation. It is a result about tolerability and it gets buried every time.

replysharereportpermalink
u/yara_bakken7 points·2 months ago

discontinuation rate is a result, not a footnote

replysharereportpermalink
u/nikhil_lindqvist61 points·2 months ago

How long was the randomised phase before any extension?

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.